Latest Asx News

AUCyber Limited has recommended shareholders accept an increased cash takeover offer from 5G Networks Limited, raising the bid by 22.7% to 13.5 cents per share amid ongoing financial uncertainties.

Atlas Arteria reports solid traffic and toll revenue growth in Q4 2024, led by strong light vehicle volumes and strategic toll increases across its global portfolio.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Agrimin Limited has achieved a major milestone with Western Australian state environmental approval for its Mackay Potash Project, alongside government-backed financial support and strategic progress toward project execution.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Babylon Pump & Power Ltd reports robust H1 FY25 results with $1.8M positive operating cash flow and $3.0M EBITDA, overcoming nickel sector challenges. The company eyes growth through new projects and acquisitions.

Agrimin Limited's latest quarterly cash flow report reveals a significant reduction in cash reserves alongside ongoing operational expenditures, prompting plans for further capital raising to maintain project momentum.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Stelar Metals advances exploration at its Baratta Copper Project with new geophysical targets identified in the Bibliando Diapir, reinforcing its potential as a sediment-hosted copper province akin to Africa’s Central Copper Belt.